Scios Nova Inc. regulatory update

The PTO ruled that SCIO's work on the human DNA sequences of bFGF was patentably distinct from Salk's work on the bovine protein and that SCIO is entitled to a patent containing claims covering DNA molecules that encode human bFGF; expression vectors containing the DNA; transformed cells of microbes containing the expression vectors and the method of producing human FGF by recombinant expression. SCIO is seeking a partner to develop the bFGF program.

Salk is entitled to DNA sequences encoding the bovine protein. A spokesperson said the institute has not yet decided whether to appeal. ...